Expression of biomarkers vimentin and Metastasis Associated 1(MTA1) protein in different stages of laryngeal cancer and their impacts on survival

Abstract

Laryngeal cancer is the second most common cancer after the lip and oral cavity cancer ofhead and neck region1. Laryngeal malignancy is the seventh most common malignancy in males in India. Total number of new laryngeal cancer and death from laryngeal cancer have been estimated 12410 and 3760 respectively in 20192. As per last survey available the number of new cases diagnosed and total number of deaths from laryngeal malignancy were 25,460 and 17,560 respectively in 2012 in India3 . The incidence of cancer larynx is 1.26-8.18 per 100,000 populations in different regions of India. Carcinoma larynx constitutes40% of all Head and Neck cancers. Squamous cell carcinoma constitutes 95% of all malignancies of larynx. Glottis being the most common subsite followed by supraglottis and the least common site is the subglottis. There is an increasing incidence rate of this malignancy among middle aged and elderly men and women throughout the world. Expression of Biomarkers at different stages of laryngeal cancers and their impact on survival can play a crucial role in future management of laryngeal malignancies. In spite of having different modalities of treatments like surgery, radiotherapy, chemoradiation, the prognosis of laryngeal malignancies is still poor. The most common adverse factor for laryngeal cancer has been found lymph node metastasis. The process of progression of LSCC is complex and difficult to know it completely. Despite multi-modality therapeutic advances in recent decades, improvements in overall survival and disease free survival is very less. In this study we emphasized the role of expression of biomarkers vimentin and metastasis associated 1(MTA1) protein in different stages of laryngeal cancer and their impacts on survival.